Sequana announces granting of a key additional methods and formulation patent for DSR. This patent increases durability and expands protection of Sequana's DSR IP, thereby improving its value. We note that the patent provides additional time for Sequana to secure dedicated financing to advance DSR toward the randomized controlled portion of the MOJAVE clinical study. We reiterate our BUY rating.
A director at EVS Broadcast Equipment SA sold 9,750 shares at 35.120EUR and the significance rating of the trade was 77/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
How to start 2026? We have selected for the KBC Securities Dynamic Top Pick List 12 large-cap companies — AB InBev, Aedifica, Argenx, ASMi, Azelis, DEME, D'Ieteren, Shurgard, Sofina, Vopak, WDP, and Wolters Kluwer — along with 3 small and mid-cap names (under €1.5bn in market capitalization): Corbion, EVS, and IBA. So, going into 2026, we maintain a balanced approach in our Dynamic Top Pick List, featuring 8 cyclical and 6 defensive stocks, with a particular emphasis on value stocks that have b...
This conference book is your guide to our annual Local Champions Mid Cap Conference set to take place on Thursday, 11 December 2025 at our historic building at Grand Place in Brussels. This event offers the possibility to have one-on-one meetings and/or attend small group sessions with the top management and/or IR of the following companies: BARCO | BEKAERT | DECEUNINCK | DEME | EVS | IBA | JENSEN GROUP | MATERIALISE | ONTEX | PROXIMUS | RECTICEL | XFAB
Colruyt: Only 5 stores left to divest in France. EVS: Lower end of the range becomes the base case, on longer lead times. Fagron: Two EMEA acquisitions and California license for FSS. Kinepolis: “Wicked” achieves solid box office. OCI: Divesting Rotterdam ammonia terminal for €290m. Prosus: 1HFY26 results – on track
Sequana reported the first US commercial alfapump implant at Mount Sinai Hospital in New York. This important milestone shows the demand for the alfapump in the US. We adjust our TP from € 2.8 to € 2.7 to reflect the new share count and reiterate our BUY rating.
Without giving exact numbers, EVS indicated they delivered y/y growth in 3Q25 revenue, offsetting the impact of major events in 3Q24 and signalling recovery from the delays seen in 1H25. Strong order intake for 4Q25 supports confidence in full-year growth, allowing EVS to reaffirm its revenue guidance of € 195m–€ 210m. That said, company-specific factors for 2025 point toward the lower end of the range as some 2025 orders may slip into 2026, reflecting longer lead times between order intake and ...
The tariff war has eased, but with Trump, uncertainty has become a guarantee. While the macro-economic impact has been limited so far, the prolonged situation could still result in significant and long-lasting economic damage. We are maintaining a defensive stance in our Benelux Dynamic Top Pick List. The Federal Reserve (FED) has started its easing cycle, but the final amount of interest rate cuts is uncertain. The European Central Bank (ECB) has now largely completed its interest rate cutting ...
In a world in which organic trends are slowing down, Eurocommercial Properties' results showed its LFL growth accelerated in 3Q25 thanks to successful remerchandising projects in Woluwe and Carosello - indicating improved performance in terms of footfall, retailer sales and renegotiations. OCR remains light and best-in-class at 10%, leaving room for future rental income growth. On the back of these 9M results, we fine-tune our estimates making limited changes only (2025F EPS up 0.5%). Valuation ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.